ArticleBMC infectious diseases2025
Rapid laboratory confirmation of the 2025 Sudan Virus Disease (Svd) index case in Uganda.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The Role of Mortality Surveillance in Case Detection and Response During the 2025 Sudan Virus Disease Outbreak in Uganda.Journal of epidemiology and global health · 2026Article
- Chandipura virus encephalitis: an emerging pediatric neurotropic threat in india-virology, epidemiology, pathogenesis, and public health challenges.Journal of neurovirology · 2026Review
- Clinical profile and genomic characterization of the 2026 Bundibugyo virus index case in Uganda.Nature medicine · 2026Article
- Review
- The Silent Risk of Sudan Virus: A Review Addressing Global Health Vulnerabilities.Health science reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Funding
Abstract
backgroundOn January 30, 2025, the Uganda Ministry of Health declared an outbreak of Sudan virus disease (SVD) following laboratory confirmation from postmortem samples of a suspected case identified through routine mortality surveillance for viral hemorrhagic fevers (VHFs) at Mulago National Referral Hospital, Kampala. This report describes the laboratory procedures used to confirm the 2025 SVD index case, emphasizing the vital role of rapid diagnostics in containing VHFs.
methodsWe leveraged existing surveillance infrastructure to collect, package, transport, test, and report results for the index-confirmed case. Testing was conducted within the framework of the established laboratory quality and bio-risk management system at the Central Emergency Response and Surveillance Laboratory. The workflow consisted of sample delivery, reception, preparation, nucleic acid extraction, master mix preparation, quantitative reverse transcriptase polymerase chain Reaction (RT-qPCR), differential diagnosis for VHFs, parallel PCR testing and typing for Sudan virus (SUDV) confirmation, result validation, and reporting.
resultsThe sample tested negative for Marburg, Yellow fever, Rift Valley fever, and Crimean-Congo Hemorrhagic Fever viruses. However, it tested positive for SUDV. Four parallel tests utilizing the Real Star® Filovirus Screen RT-PCR Kit 1.0 (Altona Diagnostics GmbH, Hamburg, Germany) on CFX96 Bio-Rad platforms, with varying sample volumes (140 µL, 90 µL, 50 µL, and 30 µL diluted with nuclease-free water), confirmed the presence of SUDV. The 50 µL sample had the lowest Ct values for the Orthoebolavirus target, while the 30 µL sample had the lowest Ct values for the internal control target. The turnaround time, from sample reception to results reporting to the Ministry of Health leadership, was less than 12 h.
conclusionMortality surveillance of VHFs is vital for the swift identification of Filovirus outbreaks in high-risk areas. Comprehensive VHFs panel testing is crucial for detecting pathogens in suspected cases. Sample dilution impacts diagnostic sensitivity, making optimized testing protocols crucial for precise molecular diagnostics. A rapid turnaround time is critical to outbreaks, enabling timely public health decisions such as case isolation, contact tracing, and resource allocation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.